Immunocidin® with Chemotherapy Extends Survival Time in Study with Canine Lymphoma and Osteosarcoma Patients
Positive data from a retrospective study using Immunocidin® with chemotherapy in dogs with Lymphoma and Osteosarcoma were presented at the Veterinary Cancer Society Annual Conference by Dr. Jeannette Kelly, vet oncologist.
Amplimune® Administered in Calves Prior to Shipment Shows Economic Benefit
Data from a University of Minnesota research study presented by Dr. Luciano Caixeta at the AABP annual conference in St. Louis, MO last week shows an economic benefit to the use of Amplimune in calves prior to shipping.
Amplimune® Administered in Calves Prior to Shipment Demonstrates a Reduced Likelihood of Pneumonia Upon Arrival
Amplimune® given to calves prior to shipment has been shown to reduce the likelihood of pneumonia on arrival. Data from a 1,360-calf study was presented at the 2019 American Dairy Science Association Annual Meeting today.
ISU College of Veterinary Medicine to Conduct a Study with Immunocidin® in the Treatment of Canine Hemangiosarcoma
NovaVive's anticancer immunotherapeutic for dogs will be evaluated in a clinical study at Iowa State University (ISU) College of Veterinary Medicine in the treatment of splenic hemangiosarcoma (in combination with chemo).
It's World Antibiotic Awareness Week and NovaVive is doing its part to help address the concern about antibiotic resistance by offering antibiotic alternatives for animals to the veterinary community and livestock/pet owners.
Amplimune® Receives Canadian OMRI Listing for Use in Organic Cattle Production
The Company's regulator-approved immunotherapy for calf scours, Amplimune®, has received an Organic Materials Review Institute (OMRI) Listing in Canada. This means that Amplimune may be used in organic cattle production.